Lv6
2850 积分 2024-09-23 加入
Azurocidin-1 as a mediator of bronchiectasis severity, epithelial defence, and target of dipeptidyl peptidase-1 inhibition: an international, multicohort study
1个月前
已关闭
Ten unanswered questions about dipeptidyl peptidase-1 inhibition in bronchiectasis
2个月前
已完结
Clearing the air: Clarifying data and interpretations from the ASPEN trial of brensocatib in bronchiectasis
2个月前
已完结
[China lymphoma diagnosis and treatment guideline (2026 edition)]
3个月前
已完结
Diffuse Large B-Cell Lymphoma
3个月前
已完结
One Pivotal Trial, the New Default Option for FDA Approval — Ending the Two-Trial Dogma
3个月前
已完结
An Intravenous Brain-Penetrant Enzyme Therapy for Mucopolysaccharidosis II
3个月前
已完结
An Intravenous Brain-Penetrant Enzyme Therapy for Mucopolysaccharidosis II
4个月前
已完结
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial
4个月前
已完结
Surrogate end points in oncology: aligning drug development incentives and patient needs
4个月前
已关闭
皖公网安备34019202002308
